MaxCyte (NASDAQ:MXCT - Free Report) had its price target decreased by Stifel Nicolaus from $11.00 to $9.00 in a report released on Wednesday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.
MaxCyte Stock Performance
Shares of NASDAQ:MXCT traded down $0.12 during midday trading on Wednesday, reaching $3.06. 628,716 shares of the company's stock traded hands, compared to its average volume of 625,825. The company has a fifty day simple moving average of $4.19 and a two-hundred day simple moving average of $3.98. MaxCyte has a 1 year low of $2.76 and a 1 year high of $5.26. The company has a market cap of $324.23 million, a P/E ratio of -9.00 and a beta of 1.35.
Institutional Trading of MaxCyte
A number of institutional investors and hedge funds have recently modified their holdings of MXCT. Franklin Resources Inc. acquired a new stake in shares of MaxCyte in the third quarter worth approximately $260,000. Barclays PLC lifted its position in MaxCyte by 329.3% in the third quarter. Barclays PLC now owns 165,765 shares of the company's stock valued at $645,000 after buying an additional 127,156 shares during the last quarter. Geode Capital Management LLC increased its position in shares of MaxCyte by 2.0% during the third quarter. Geode Capital Management LLC now owns 2,474,632 shares of the company's stock valued at $9,628,000 after acquiring an additional 47,960 shares during the last quarter. Mudita Advisors LLP increased its position in shares of MaxCyte by 5.6% during the third quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company's stock valued at $12,267,000 after acquiring an additional 167,101 shares during the last quarter. Finally, State Street Corp raised its stake in shares of MaxCyte by 5.1% in the 3rd quarter. State Street Corp now owns 2,269,135 shares of the company's stock valued at $8,827,000 after acquiring an additional 111,066 shares during the period. Hedge funds and other institutional investors own 68.81% of the company's stock.
MaxCyte Company Profile
(
Get Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Further Reading
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
